Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
INO's Cash to Debt is ranked higher than
95% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. INO: No Debt )
Ranked among companies with meaningful Cash to Debt only.
INO' s 10-Year Cash to Debt Range
Min: 0.97  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.90
INO's Equity to Asset is ranked higher than
82% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. INO: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
INO' s 10-Year Equity to Asset Range
Min: 0.44  Med: 0.80 Max: 0.95
Current: 0.9
0.44
0.95
Interest Coverage No Debt
INO's Interest Coverage is ranked higher than
91% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
INO' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 13.84
M-Score: -1.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -290.36
INO's Operating margin (%) is ranked lower than
65% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. INO: -290.36 )
Ranked among companies with meaningful Operating margin (%) only.
INO' s 10-Year Operating margin (%) Range
Min: -8188.89  Med: -321.72 Max: -82.67
Current: -290.36
-8188.89
-82.67
Net-margin (%) -213.00
INO's Net-margin (%) is ranked lower than
63% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. INO: -213.00 )
Ranked among companies with meaningful Net-margin (%) only.
INO' s 10-Year Net-margin (%) Range
Min: -5759.26  Med: -316.04 Max: -79.32
Current: -213
-5759.26
-79.32
ROE (%) -24.80
INO's ROE (%) is ranked higher than
55% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. INO: -24.80 )
Ranked among companies with meaningful ROE (%) only.
INO' s 10-Year ROE (%) Range
Min: -243.7  Med: -68.95 Max: -32.52
Current: -24.8
-243.7
-32.52
ROA (%) -21.58
INO's ROA (%) is ranked higher than
55% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. INO: -21.58 )
Ranked among companies with meaningful ROA (%) only.
INO' s 10-Year ROA (%) Range
Min: -98.97  Med: -40.82 Max: -25.77
Current: -21.58
-98.97
-25.77
ROC (Joel Greenblatt) (%) -884.57
INO's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. INO: -884.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7552.88  Med: -3613.23 Max: -481.97
Current: -884.57
-7552.88
-481.97
Revenue Growth (3Y)(%) -16.60
INO's Revenue Growth (3Y)(%) is ranked lower than
66% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. INO: -16.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -78  Med: -16.60 Max: 180.2
Current: -16.6
-78
180.2
EBITDA Growth (3Y)(%) 1.10
INO's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. INO: 1.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
INO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -28.1  Med: -16.60 Max: 15.7
Current: 1.1
-28.1
15.7
EPS Growth (3Y)(%) 8.30
INO's EPS Growth (3Y)(%) is ranked higher than
66% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. INO: 8.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
INO' s 10-Year EPS Growth (3Y)(%) Range
Min: -40.3  Med: -14.30 Max: 57.1
Current: 8.3
-40.3
57.1
» INO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

INO Guru Trades in Q1 2014

Paul Tudor Jones 31,085 sh (New)
First Eagle Investment Sold Out
» More
Q2 2014

INO Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
» More
Q3 2014

INO Guru Trades in Q3 2014

Paul Tudor Jones 12,215 sh (New)
» More
Q4 2014

INO Guru Trades in Q4 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.98
INO's P/B is ranked higher than
63% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. INO: 2.98 )
Ranked among companies with meaningful P/B only.
INO' s 10-Year P/B Range
Min: 0.38  Med: 2.86 Max: 13.16
Current: 2.98
0.38
13.16
P/S 31.79
INO's P/S is ranked lower than
74% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. INO: 31.79 )
Ranked among companies with meaningful P/S only.
INO' s 10-Year P/S Range
Min: 1.57  Med: 17.13 Max: 102.4
Current: 31.79
1.57
102.4
Current Ratio 11.17
INO's Current Ratio is ranked higher than
79% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. INO: 11.17 )
Ranked among companies with meaningful Current Ratio only.
INO' s 10-Year Current Ratio Range
Min: 0.82  Med: 3.78 Max: 16.04
Current: 11.17
0.82
16.04
Quick Ratio 11.17
INO's Quick Ratio is ranked higher than
80% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. INO: 11.17 )
Ranked among companies with meaningful Quick Ratio only.
INO' s 10-Year Quick Ratio Range
Min: 0.82  Med: 3.55 Max: 16.04
Current: 11.17
0.82
16.04
Days Sales Outstanding 138.79
INO's Days Sales Outstanding is ranked lower than
82% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. INO: 138.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
INO' s 10-Year Days Sales Outstanding Range
Min: 6.24  Med: 78.71 Max: 788.58
Current: 138.79
6.24
788.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.03
INO's Price/Net Cash is ranked higher than
69% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. INO: 4.03 )
Ranked among companies with meaningful Price/Net Cash only.
INO' s 10-Year Price/Net Cash Range
Min: 2.25  Med: 8.91 Max: 288
Current: 4.03
2.25
288
Price/Net Current Asset Value 3.82
INO's Price/Net Current Asset Value is ranked higher than
70% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. INO: 3.82 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
INO' s 10-Year Price/Net Current Asset Value Range
Min: 2.05  Med: 7.50 Max: 115.2
Current: 3.82
2.05
115.2
Price/Tangible Book 3.24
INO's Price/Tangible Book is ranked higher than
66% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. INO: 3.24 )
Ranked among companies with meaningful Price/Tangible Book only.
INO' s 10-Year Price/Tangible Book Range
Min: 1.44  Med: 4.93 Max: 20.92
Current: 3.24
1.44
20.92
Price/Projected FCF 32.57
INO's Price/Projected FCF is ranked lower than
89% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. INO: 32.57 )
Ranked among companies with meaningful Price/Projected FCF only.
INO' s 10-Year Price/Projected FCF Range
Min: 35.48  Med: 35.48 Max: 35.48
Current: 32.57
Price/Median PS Value 1.90
INO's Price/Median PS Value is ranked lower than
76% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. INO: 1.90 )
Ranked among companies with meaningful Price/Median PS Value only.
INO' s 10-Year Price/Median PS Value Range
Min: 0.24  Med: 0.98 Max: 58.82
Current: 1.9
0.24
58.82
Earnings Yield (Greenblatt) (%) -11.07
INO's Earnings Yield (Greenblatt) (%) is ranked lower than
62% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. INO: -11.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -13.48  Med: 0.00 Max: 0
Current: -11.07
-13.48
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 24 18 62
EPS($) -0.64 -0.98 -0.08
EPS without NRI($) -0.64 -0.98 -0.08

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GBMB.Germany,
Inovio Pharmaceuticals Inc was originally incorporated on June 29, 1983, under the laws of California as Biotechnologies & Experimental Research, Inc. The entity changed its corporate name to BTX, Inc. on December 10, 1991, and Genetronics, Inc. on February 8, 1994. On April 14, 1994, the board of directors approved a share exchange agreement with Consolidated United Safety Technologies Inc. On September 2, 1997, it listed on the Toronto Stock Exchange as Genetronics Biomedical Ltd, under the laws of British Columbia, Canada, which wholly owned Genetronics, Inc. On June 15, 2001, it completed a change in jurisdiction of incorporation from British Columbia, Canada, to the state of Delaware and became Genetronics Biomedical Corporation, a Delaware corporation. On January 17, 2003, Genetronics voluntarily de-listed from the Toronto Stock Exchange. On March 31, 2005, its corporate name changed from Genetronics Biomedical Corporation to Inovio Biomedical Corporation. On June 1, 2009, it completed the acquisition of VGX Pharmaceuticals, Inc. ('VGX'), a privately-held company, pursuant to the terms of an Amended and Restated Agreement and Plan of Merger dated December 5, 2008, as further amended on March 31, 2009 by and among Inovio, Inovio's wholly-owned subsidiary Inovio Acquisition, LLC and VGX (the 'Merger'). Upon the closing of the Merger, Inovio Acquisition, LLC assumed all of VGX's business, properties and assets and assumed its obligations, changed its name to VGX Pharmaceuticals, LLC, and remains a wholly-owned subsidiary of the Company, utilizing a single, integrated management team with Inovio. On May 14, 2010, the entity changed its corporate name to Inovio Pharmaceuticals, Inc. The Company is engaged in the development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. Its DNA-based SynCon technology is designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with its proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Its preclinical development and clinical programs include cervical dysplasia/cancer (therapeutic), influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. The Company faces competition from several development-stage and established enterprises, including major pharmaceutical and biotechnology firms, which are actively engaged in infectious disease and cancer vaccine research and development. Any pharmaceutical products that the Company develops will require regulatory clearances prior to clinical trials and additional regulatory approvals prior to commercialization. The Company's clinical programs include cervical dysplasia (therapeutic), avian influenza (preven
» More Articles for INO

Headlines

Articles On GuruFocus.com
Inovio Pharmaceuticals' CEO Dr. J. Joseph Kim Interviewed by The Life Sciences Report Oct 30 2014 
Inovio CEO Invests in 250,000 Shares of Company Stock Aug 13 2014 
comment on INO May 10 2013 
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CFO Buys Highlight: ZBB, INO, LPR, PMC, FGP, PRMW Jun 17 2012 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
Any opinions regarding Apr 12 2010 

More From Other Websites
How Does Novavax Compare to Its Competitors? Aug 31 2015
Medimmune enters into strategic cancer vaccine collaboration and license agreement with Inovio... Aug 29 2015
Inovio Pharmaceuticals to Participate in Citi and Rodman & Renshaw Investor Conferences Aug 26 2015
Inovio Pharmaceuticals to Participate in Citi and Rodman & Renshaw Investor Conferences Aug 26 2015
INOVIO PHARMACEUTICALS, INC. Financials Aug 21 2015
Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio Aug 21 2015
Inovio Reports Encouraging Preclinical Data on DNA Vaccine Aug 20 2015
Sentiment for Advaxis Back to Bullish With Broadfin and Inovio Deal Aug 20 2015
Inovio Pharmaceuticals DNA Vaccine Protects 100% Against Deadly MERS Virus in Non-Human Primates Aug 20 2015
Inovio Pharmaceuticals DNA Vaccine Protects 100% Against Deadly MERS Virus in Non-Human Primates Aug 19 2015
Is this CEO going to take on Trump? Aug 14 2015
Corporate Document-Corporate Profile for Inovio Pharmaceuticals, Inc. Aug 13 2015
INOVIO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 12 2015
MedImmune Deal Validates Inovio's Cancer Tech Aug 11 2015
Inovio Q2 Loss Wider-than-Expected, Deal with AstraZeneca - Analyst Blog Aug 11 2015
Jim Cramer's Top Takeaways: Radius Health, Inovio Pharmaceuticals Aug 11 2015
Jim Cramer's 'Mad Money' Recap: 10 Things That Created Today's Market Rally Aug 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK